Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nal-IRI + TAS-102 in Refractory Solid Tumors
NCT03810742Phase 1Completed
- Sponsor
- PharmaEngine, Inc.
- Start
- Mar 2019
- Primary completion
- May 2022
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nanoliposomal irinotecan in solid tumor, sponsored by PharmaEngine, Inc. Primary endpoints: Dose Limiting Toxicities at 12 months and Incidence of Treatment-Emergent Adverse Events at 12 months. Started Mar 2019; status: completed.
02
Drugs
nanoliposomal irinotecan
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03810742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03810742.